M6PR | Mannose-6-phosphate receptor (cation dependent) | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
MAOA | Monoamine oxidase A | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | | | | Mixed |
MAP2 | Microtubule-associated protein 2 | FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
MAP2K2 | Mitogen-activated protein kinase kinase 2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
MET | MET proto-oncogene, receptor tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Expressed in all |
MS4A1 | Membrane-spanning 4-domains, subfamily A, member 1 | CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
NFKB1 | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins RAS pathway related proteins Transcription factors
| | | | | Expressed in all |
NOS3 | Nitric oxide synthase 3 (endothelial cell) | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
NR3C1 | Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) | Disease related genes FDA approved drug targets Nuclear receptors Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
PDGFRB | Platelet-derived growth factor receptor, beta polypeptide | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
PDXK | Pyridoxal (pyridoxine, vitamin B6) kinase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PLA2G4A | Phospholipase A2, group IVA (cytosolic, calcium-dependent) | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Mixed |
PLIN3 | Perilipin 3 | FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PNP | Purine nucleoside phosphorylase | Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
PRDX5 | Peroxiredoxin 5 | Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PRKAB1 | Protein kinase, AMP-activated, beta 1 non-catalytic subunit | FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
PSMB1 | Proteasome (prosome, macropain) subunit, beta type, 1 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PSMB8 | Proteasome (prosome, macropain) subunit, beta type, 8 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PSMD1 | Proteasome (prosome, macropain) 26S subunit, non-ATPase, 1 | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
PSMD2 | Proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
PTGS1 | Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) | Cancer-related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
QPRT | Quinolinate phosphoribosyltransferase | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
RPL3 | Ribosomal protein L3 | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins Ribosomal proteins
| | | | | Expressed in all |
RRM2B | Ribonucleotide reductase M2 B (TP53 inducible) | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
SIGMAR1 | Sigma non-opioid intracellular receptor 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
SIRT5 | Sirtuin 5 | FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
SOAT1 | Sterol O-acyltransferase 1 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
SRC | SRC proto-oncogene, non-receptor tyrosine kinase | Cancer-related genes Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Mixed |
SV2A | Synaptic vesicle glycoprotein 2A | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
TBXAS1 | Thromboxane A synthase 1 (platelet) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
TNFRSF8 | Tumor necrosis factor receptor superfamily, member 8 | Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
TOP1 | Topoisomerase (DNA) I | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
TOP2A | Topoisomerase (DNA) II alpha 170kDa | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
TOP2B | Topoisomerase (DNA) II beta 180kDa | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
TUBA1A | Tubulin, alpha 1a | Cancer-related genes Disease related genes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
TUBA4A | Tubulin, alpha 4a | FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
TUBB | Tubulin, beta class I | Cytoskeleton related proteins Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
TUBG1 | Tubulin, gamma 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
TYR | Tyrosinase | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |